Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Liabilities and Shareholders Equity (2017 - 2025)

Bioceres Crop Solutions' Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $763.6 million for Q2 2025.

  • For Q2 2025, Liabilities and Shareholders Equity fell 10.43% year-over-year to $763.6 million; the TTM value through Jun 2025 reached $3.0 billion, up 34.89%, while the annual FY2025 figure was $763.6 million, 10.43% down from the prior year.
  • Liabilities and Shareholders Equity for Q2 2025 was $763.6 million at Bioceres Crop Solutions, down from $852.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $852.5 million in Q2 2024 and bottomed at $394.6 million in Q2 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $763.6 million (2025), against an average of $669.4 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 57.86% in 2023 before it fell 10.43% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $394.6 million in 2021, then soared by 31.33% to $518.2 million in 2022, then surged by 57.86% to $818.1 million in 2023, then increased by 4.22% to $852.5 million in 2024, then decreased by 10.43% to $763.6 million in 2025.
  • Per Business Quant, the three most recent readings for BIOX's Liabilities and Shareholders Equity are $763.6 million (Q2 2025), $852.5 million (Q2 2024), and $818.1 million (Q2 2023).